# Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

> **NCT00594347** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 339 (actual)

## Conditions studied

- Streptococcus Pneumoniae

## Interventions

- **BIOLOGICAL:** Pneumo 23
- **BIOLOGICAL:** Prevnar

## Key facts

- **NCT ID:** NCT00594347
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-03
- **Final completion:** 2009-04
- **Target enrollment:** 339 (ACTUAL)
- **Last updated:** 2015-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00594347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00594347, "Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00594347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*